Open access
Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies.
Gordon Sussman
N. Chapman-Rothe
Tao Ding
A. Fukunaga
A. Giménez-Arnau
M. Hide
M. Lebwohl
P. Machado
E. Martzloff
Giselle S. Mosnaim
C. Ortmann
P. Staubach
Hui Tang
A. Weyergraf
Bin Yang
John Reed
Medicine
Abstract
We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.